Urinary 11-Dehydrothromoboxane B2: A Quantitative Index of Platelet Activation in Cerebral Infarction

Abstract

Thromboxane A2 (TXA2) biosynthesis was studied in healthy subjects, patients with chronic cerebral infarction, patients under chronic aspirin treatment and patients with atrial fibrillation. Urinary 11-dehydro-TXB2, as a major metabolite of TXA2, was measured by radioimmunoassay. The extent of carotid atherosclerosis was determined by B-mode ultrasonography. The mean ± SD urinary excretion in patients with cerebral infarction and distinct carotid-atherosclerotic lesions (1,725 ± 239 ng/g creatinine, n = 6) was significantly higher (p<0.01) than in healthy subjects (911 ± 239 ng/g creatinine, n = 44) and patients with cerebral infarction who had no distinct carotid lesion (1,050 ± 191 ng/g creatinine, n = 6). The urinary excretion of healthy subjects was higher (p < 0.01) in smokers (1,063 ± 244 ng/g creatinine, n = 17) than in non-smokers (815 ± 183 ng/g creatinine, n = 27). Aspirin largely suppressed 11-dehydro-TXB2 excretion (266 ± 114 ng/g creatinine, n = 7). Three of 5 patients with atrial fibrillation showed very high values. Our results indicated that platelet activation occurs in the atherosclerotic lesions, and that urinary 11-dehydro-TXB2 is the appropriate analytic target for detecting platelet activation. (Internal Medicine 31: 735-739, 1992). © 1992, The Japanese Society of Internal Medicine. All rights reserved.